Pediatric Preclinical Testing Consortium
Point of Contact: Malcolm Smith, M.D., Ph.D., smithm@ctep.nci.nih.gov
Program
The Pediatric Preclinical Testing Consortium (PPTC) is addressing the unmet need of streamlining the development of new therapies for childhood cancers. The PPTC seeks to develop robust biomarkers of anticancer drug activity, and the majority of these are predicted to be genetic mutations that can be detected in tumor DNA and/or RNA. In order to design the most impactful experiments that can be rapidly translated to the clinic, PPTC investigators require a complete genomic characterization of the patient-derived xenograft tumor models that are utilized across the consortium. This will not only allow for the most robust experimental design, but also will increase the engagement of industry partners who seek collaborators poised to provide the proof-of-concept necessary for drugs in their development pipelines.
Resource Description
Resource Type
Program
Specialization
Pediatric
Data Update Date
08/05/2024
Data Content Type
Clinical, Genomics/Omics, Xenograft
Resource Tools
Visualization Tools
Analytic Tools
Data Access
Case Disease Diagnosis
Alveolar Rhabdomyosarcoma (5); Alveolar Soft Part Sarcoma (2); Astrocytoma, NOS (3); Atypical Teratoid/Rhabdoid Tumor (8); B Lymphoblastic Leukemia/Lymphoma with T(9;22)(Q34;Q11.2); BCR-ABL1 (3); B Lymphoblastic Leukemia/Lymphoma with T(V;11Q23); Mll Rearranged (10); B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like (17); B Lymphoblastic Leukemia/Lymphoma, NOS (30); Carcinoma, NOS (1); Clear Cell Sarcoma, NOS (1) ...
Number of Cases
267
Case Sex
Female (90); Male (169); Not Reported (8)
Case Age At Diagnosis
0 to 4 years (86); 5 to 9 years (46); 10 to 14 years (50); 15 to 19 years (31); 20 to 24 years (5); 25 to 29 years (1); Pediatric and Young Adult (<40 years) (48)
Published In
Project